API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.biopharmadive.com/news/novartis-branaplam-huntingtons-disease-safety-suspend-dosing/630423/
https://www.novartis.com/news/media-releases/novartis-receives-us-food-and-drug-administration-fda-orphan-drug-designation-branaplam-lmi070-huntington%27s-disease-hd
https://www.reuters.com/article/us-novartis-branaplam-huntingtons-s-dise/novartis-to-pursue-sma-drug-branaplam-in-huntingtons-disease-idUSKBN2760KN
https://www.reuters.com/article/us-novartis-investors-sma/novartis-rd-boss-says-doesnt-see-big-opportunity-in-oral-sma-therapy-idUSKBN1Y91S0
https://endpts.com/genentech-takes-aim-at-biogen-and-novartis-highlighting-an-early-look-at-positive-results-for-their-oral-sma-drug-from-ptc/